2-Apr-2026
Globe Newswire (Mon, 23-Mar 7:00 AM ET)
Globe Newswire (Tue, 3-Feb 6:45 AM ET)
PYXS Showcases Strong Early Data in Precision Oncology—Key Metrics Point to Industry Momentum
Market Chameleon (Mon, 12-Jan 5:32 AM ET)
The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff
Globe Newswire (Mon, 12-Jan 10:14 AM ET)
Market Chameleon (Mon, 3-Nov 5:38 AM ET)
Pyxis Oncology Appoints Experienced Capital Markets Leader Alex Kane to Steer Investor Relations
Market Chameleon (Thu, 9-Oct 7:19 AM ET)
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.
Pyxis Oncology trades on the NASDAQ stock market under the symbol PYXS.
As of April 2, 2026, PYXS stock price climbed to $1.48 with 176,831 million shares trading.
PYXS has a beta of 1.58, meaning it tends to be more sensitive to market movements. PYXS has a correlation of 0.03 to the broad based SPY ETF.
PYXS has a market cap of $92.99 million. This is considered a Micro Cap stock.
In the last 3 years, PYXS traded as high as $6.85 and as low as $.83.
The top ETF exchange traded funds that PYXS belongs to (by Net Assets): VTI, VXF, IBB, IWC, IBBQ.
PYXS has outperformed the market in the last year with a return of +45.1%, while the SPY ETF gained +17.5%. In the last 3 month period, PYXS beat the market returning +28.7%, while SPY returned -3.7%. However, in the most recent 2 weeks PYXS has underperformed the stock market by returning -3.9%, while SPY returned -0.1%.
PYXS support price is $1.39 and resistance is $1.55 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PYXS shares will trade within this expected range on the day.
